COMPASS Pathways

CMPS Small Cap

Healthcare · Medical Care Facilities

Aktualisiert: Apr 5, 2026, 17:43 UTC

$5.79

+3.02% heute

52W: $2.25 – $8.90

52W Low: $2.25 Position: 53.2% 52W High: $8.90

🔗 Broker vergleichen

Kennzahlen

P/E Ratio

—

Kurs/Gewinn-Verhältnis

Forward P/E

—

Erwartetes KGV

P/S Ratio

—

Kurs/Umsatz-Verhältnis

EV/EBITDA

—

Unternehmenswert/EBITDA

Dividendenrendite

—

Jährl. Dividendenrendite

Market Cap

$746.5M

Marktkapitalisierung

Umsatzwachstum

—

YoY Umsatzwachstum

Gewinnmarge

—

Nettomarge

ROE

-565.28%

Eigenkapitalrendite

Beta

2.02

Marktsensitivität

Short Interest

5.71%

% der Aktien leerverkauft

Ø Volumen

2,931,204

Durchschn. Tagesvolumen

Bewertungs-Analyse

Signal

N/A

vs. S&P 500 Ø KGV (24.7x)

Analysten-Konsens

Starker Kauf

12 Analysten

Ø Kursziel

$21.75

+275.65% Upside

Kursziel Spanne

$8.00 – $70.00

Über das Unternehmen

COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.

Sektor: Healthcare Branche: Medical Care Facilities Land: United Kingdom Mitarbeiter: 156 Börse: NMS

Trading-Daten

50-Day MA: $6.56

200-Day MA: $5.65

Volumen: 1,290,633

Ø Volumen: 2,931,204

Short Ratio: 1.18

Kurs/Buchwert: —

Verschuldung/EK: —

Free Cash Flow: $97.1M

Wo kann ich COMPASS Pathways kaufen?

Vergleiche die besten Broker — niedrige Gebühren, seriöse Anbieter, reguliert.

Broker vergleichen →